Iris 93 microbiota fitness) to microbiota density, we utilized germ-free mice with controlled host carrying 94 capacity (i.e., fixed diet, genetics, and environment) transplanted with the microbiotas of different 95 mammals. Although there are clear caveats to assaying properties of the microbiota in a non-native 96 host, several prior studies have demonstrated that germ-free microbiota transplantations from other 97 mammals can recapitulate many aspects of the microbial community (13-15) and even host 98 physiology (16)(17)(18)(19) in the murine host. Importantly, these microbiota transplant experiments provide 99 an experimental tool to estimate relative differences in fitness between microbiotas because each 100 microbiota is transplanted into one or more replicate murine hosts with the same carrying capacity. In 101 germ-free Swiss Webster mice colonized with four of the lowest density microbiotas in our initial 102 screen (lion, elephant, ferret, and red panda), the lion and red panda microbiotas reached higher 103 microbiota densities in the mouse than in the native host, suggesting their densities were limited by 104 the carrying capacity of their host. The elephant and ferret microbiotas colonized mice at densities 105 comparable to those in the native host and significantly less dense than a mouse microbiota ( Figure   106 1E), suggesting their densities are limited by the fitness of each microbiota that cannot reach the 107 mouse carrying capacity. Altogether, these mammalian microbiota samples and germ-free transfer 108 experiments demonstrate that as in macroecology, microbiota density represents the combined 109 influence of host carrying capacity and community fitness.
since it correlates with flow cytometry counts and colony forming units (CFU), and it can be easily 67 incorporated into standard microbiome sequencing workflows by weighing the sample (9). We 68 investigate host and microbial factors that contribute to microbiota density across a diverse set of 69 mammalian microbiomes, study the impact of microbiota density on host adiposity and immune 70 function in controlled mice models, and describe microbiota density changes in disease and the 71 resolution of those alterations after therapy.
72

Results
73
The natural variation of gut microbiota density in mammals is driven by host and microbial 74 factors 75
In macroecology, carrying capacity is the maximal density of organisms supported by an ecosystem 76 and is broadly dictated by the resources (e.g. food, water, and habitat) in the environment. Whether or 77 not the collection of species in an environment can reach the carrying capacity depends on their 78 ability to efficiently utilize the available resources (i.e., the community's fitness for the environment).
79
To explore the contribution of host carrying capacity and gut microbiota fitness to microbiota density, 80 we first collected fecal material from sixteen different mammalian species (Table S1) 
82
Using methods optimized to assay fecal microbiota density with greater throughput (see Methods and 83 Figure S1 ), we observed significant differences in microbiota density across the mammalian samples 84 (H = 69.0, p = 6.72 x 10 -9 ; Kruskal-Wallis) with a 216-fold difference between the median of the most 85 dense and least dense gut microbiota ( Figure 1A) . We found a positive correlation between microbiota 86 density and phylogenetic relatedness of the host (R 2 = 0.191; p = 0.0368; Pearson; Figure 1B ), while 87 there was no correlation between microbiota density and either fecal water content ( = -0.0418, p = 88 0.892, Spearman; Figure 1C ) or host size (mass) ( = -0.364, p = 0.167, Spearman; Figure S2 ).
89
Animals from order Carnivora (dog, ferret, lion, red panda, and tiger), with simple gut architectures 90 adapted to carnivorous diets, had significantly reduced microbiota densities compared with the rest of 91 the mammals studied (p = 6.14 x 10 -10 , Mann-Whitney, Figure 1D ).
92
To assay the relative contributions of the host (i.e., carrying capacity) and the microbiota (i.e., the same for dry and wet microbiota density vs phenotypes (i.e., the rank order of density does not 140 change when using dry weights). Furthermore, when estimating the relationships between microbiota 141 density and host physiology with linear models we find that wet weight is a better predictor of changes 142 in cecum size, epididymal fad pad mass, fecal IgA, and FoxP3 + CD4 + regulatory T cells than dry 143 weight.
144
Microbiota density in inflammatory bowel disease (IBD)
145
To characterize the impact of host health status on gut microbiota density, we collected fecal samples 146 from 70 healthy controls, 144 subjects with Crohn's disease (CD), 109 subjects with ulcerative colitis 147 (UC), and 19 subjects with UC that had undergone an ileal pouch-anal anastomosis (IPAA) procedure 148 following total colectomy. Concordant with prior work using phylum-specific qPCR (30) and flow 149 cytometry (CD-only; (10)), subjects with IBD had decreased microbiota density compared to healthy 150 controls (p < 0.001 for each vs Healthy, Kruskal-Wallis rank sum test, followed by a Dunn's test with 151 Bonferroni correction; Figure 3A ), even when excluding individuals receiving antibiotics ( Figure S4A ).
152
Individuals with active CD or UC, as well as IPAA subjects had increased fecal water content 153 compared to healthy individuals (p < 0.05 for each vs Healthy; Tukey's HSD), while individuals with 154 inactive CD or UC did not. Nonetheless, the decrease in microbiota density in IBD compared to 155 healthy controls was consistent across individuals with active disease or inactive disease (p < 0.001 156 for each vs Healthy, Kruskal-Wallis rank sum test, followed by a Dunn's test with Bonferroni 157 correction; Figure 3B ), demonstrating the microbiota density changes in IBD were not simply driven by 158 the increased fecal water content that occurred with active inflammation.
159
To associate changes in microbiota composition with the altered microbiota density in 160 individuals with IBD, we performed 16S rRNA gene amplicon sequencing of the fecal DNA ( Figure   161 3C-3D). In line with previous studies (30-33), the IBD microbiome had a decreased alpha diversity 162 compared to healthy subjects (p < 0.01 for all; Kruskal-Wallis rank sum test, followed by a Dunn's test 163 with Bonferroni correction; Figure S5 ). When we multiplied each taxa's relative abundance by the 164 microbiota density to calculate their absolute abundances, we found decreases in gut microbiota 165 density were most significantly correlated with decreases in Firmicutes, while Proteobacteria were the 166 only one of the four major phyla in the gut microbiota that were not correlated with microbiota density 167 ( Figures 3E-3H ). These results from measuring the absolute microbiota differ from common 168 observations of relative increases in Proteobacteria associated with IBD (30, 31). More accurately, it 169 appears that Proteobacteria are able to sustain a constant density in the in IBD as the other phyla 170 decrease in absolute terms.
171
Fecal microbiota transplants restore microbiota density and microbiota fitness 172 Given the large difference in the microbiota between healthy individuals and those with recurrent 173 Clostridium difficile infection (rCDI) ( Figure S6; (34, 35) ), we hypothesized that on a mechanistic level,
174
FMT bolsters colonization resistance by improving gut microbiota fitness. In fecal samples from FMT 175 donors and their rCDI FMT recipients prior to and after FMT, we observed that the rCDI gut microbiota has a significantly lower microbiota density than the donor microbiota, and that FMT increased 177 microbiota density (p < 0.05 for all comparisons, Kruskal-Wallis rank sum test, followed by a Dunn's 178 test with Bonferroni correction; Figure 4A ). We did not observe any differences in fecal water content 179 between the donors and recipients before or after FMT (p > 0.2 for all comparisons, Tukey's HSD). In 180 addition, we found that rCDI FMT recipients had both a relative and absolute increase in 181 Proteobacteria that was significantly reduced by FMT ( Figures 4B, 4C , and S6C-S6F). These data 182 suggest that FMT restores higher densities of Bacteroidetes, Firmicutes, and Actinobacteria to more 183 fully realize the host's carrying capacity. However, several factors may confound this conclusion as 184 individuals with rCDI are often on antibiotics prior to FMT.
185
To separate the host physiologic and pharmacologic factors that might impact our 186 understanding of community fitness in rCDI, we utilized a gnotobiotic murine model of FMT ( Figure   187 4D) where germ-free mice were initially colonized with the fecal material of individuals with rCDI for 3 188 weeks prior to a single transplant of fecal material via oral gavage from a second human donor -the 189 same healthy FMT donor used for the transplant clinically. As a control, we colonized germ-free mice 190 with the FMT donor microbiota alone ( Figure 4D ). The microbiota density of mice colonized with the 191 healthy samples (a) was greater than that of mice colonized with rCDI samples (b) (p < 0.001,
192
Kruskal-Wallis rank sum test, followed by a Dunn's test with Bonferroni correction; Figure 5E ),
193
suggesting that rCDI individuals have a reduced microbiota fitness compared to healthy donors.
194
Following the introduction of the healthy donor microbiota to the mice colonized with the rCDI 195 microbiota (c), we observed increased microbiota density in these mice (p < 0.001, Kruskal-
196
Wallis rank sum test, followed by a Dunn's test with Bonferroni correction; Figure 4E ), implying a 197 restoration of microbiota fitness. Furthermore, when we colonize germ-free mice with the microbiota of 198 the individuals with rCDI 6-12 months after they received an FMT (d), we find that their microbiota 199 fitness had been restored, just as in our mouse FMT model (p < 0.001, Kruskal-Wallis rank sum test,
200
followed by a Dunn's test with Bonferroni correction; Figure 4E ). These findings in the mice model 201 recapitulate the data in our human cohort of FMT recipients and suggest that FMT successfully treats 202 the fitness defect of the rCDI community.
203
Discussion
204
The DNA-based microbiota density estimation method employed here and in previous studies (9, 11, 205 12) has the advantage that it can be incorporated into existing 16S rRNA and metagenomic workflows 206 by simply weighing the input sample and ensuring the input mass of fecal material is within the linear 207 range of the DNA extraction protocol. Incorporating microbiota density into standard culture 208 independent microbiome workflows would greatly broaden our understanding of factors that drive one 209 of the most fundamental properties of any ecosystem -its population density -and it would allow the 210 broader study of absolute taxon abundances. Recent work has demonstrated that the amount of 211 live/dead bacteria can vary between fecal samples (36-38), which would not be captured by a DNA-based density metric. However, in practice we found that the influence of any variation from live/dead 213 bacteria was sufficiently low that it did not influence the major conclusions of this study; we observed 214 a very significant correlation between the viability-based CFU density measurement and the DNA-215 based one and all of the major relationships observed in this study were consistent across both 216 approaches (i.e., variation across mammals, IBD and IPAA lower density than healthy, rCDI lower 217 density than FMT donor or rCDI post-transplant; Figure S1D ).
218
Previous work has demonstrated that changes in fecal water are associated but not 219 necessarily causally influencing differences in microbiota composition across the human population 220 (39, 40) . While both fecal water content and microbiota density vary across mammals and can be 221 altered by pharmacologics ( Fig. 2, S4F ), dietary components ( Fig. S7; (12) ), and host disease status,
222
we find microbiota density is consistently not correlated with water content. In the context of altering 223 host physiology through antibiotic manipulation of microbiota density, the best predictor of the impact 224 of changes of microbiota density on host physiology was when density was calculated with stool wet 225 weight, suggesting both wet and dry components of stool are important diluents in determining 226 microbiota density and its impact on the host.
227
Differences in microbiota density can be influenced by both the host's carrying capacity and 228 the fitness of the microbiota to reach the carrying capacity of a given host. We found the density of gut 229 microbes varies across mammals and is more similar in more phylogenetically related species. Across 230 mammals, gut architecture appears to be a major driver of density, as the lowest densities were 231 observed in order Carnivora, whose short, simple intestines have a lower carrying capacity and are 232 maladapted for microbial fermentation at high densities. The low microbiota density of the red panda, 233 a member of Carnivora with a herbivorous diet, further supports intestinal architecture as a major 234 determinant of host carrying capacity and thus a driver of microbiota density. Finally, the significantly 235 reduced microbiota density in humans with IPAA uniquely demonstrates that changing gut 236 architecture within a species (in this case by surgery to treat ulcerative colitis) is equally capable of 237 influencing host carrying capacity.
238
Within a murine host with controlled carrying capacity (i.e., fixed diet, genetics, housing, etc.),
239
we found microbiota density can be altered with pharmacologics, with downstream consequences to 240 host adiposity and immune function. Different antibiotics were highly varied in their ability to impact 241 microbiota density, which could explain the mixed efficacy of antibiotics in microbiota-targeted clinical 242 trials for complex disease and varied responses to antibiotics in animal models. Identifying more 243 effective microbiota depleting cocktails would improve the design of such studies, while measuring 244 microbiota density in trials with antibiotics could better stratify clinical response. Previous studies have 245 observed that microbiota density can be manipulated by dietary changes (12, 41) . Furthermore, we 246 found that altering microbiota density with either diet or antibiotics could modify colitis severity (12).
247
Understanding the long-term effect of high or low microbiota density on health could help refine the 248 use of diet and the microbiota in disease treatment and prevention.
249
Finally, we observed that microbiota density is reduced in both IBD and rCDI. Microbiota 250 density reductions, from a lack of fitness in the microbial community, were "druggable" by FMT. The 251 ability of FMT to increase microbiota density through improved community fitness provides 252 mechanistic insights into FMT for rCDI and a novel biomarker to track its success. This result also 253 highlights that routine monitoring to identify individuals with microbiota fitness deficiencies combined 254 with prophylactic microbial therapeutics targeted might form a therapeutic strategy to boost 255 colonization resistance to treat or prevent disease.
256
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281
(D) Animals from the order Carnivora have a reduced microbiota density compared to mammals from 282 other orders.
283
(E) Different mammalian gut microbiotas transplanted into germ-free Swiss Webster mice (n = 3 per 284 group) vary in their fitness to reach microbiota densities similar to mouse microbiotas.
285
In 
309
(E-H) The absolute abundance of all of the major phyla are strongly correlated with microbiota 310 density, with the exception of Proteobacteria, whose abundance is largely constant.
311
325
(E) Microbiota density in mice from the experimental scheme described in (D) showed decrease in 326 microbiota fitness prior to FMT and an increase in microbiota density following FMT demonstrating the 327 restoration of community fitness.
328
387
Samples were centrifuged at 4000rpm for 5 minutes to separate aqueous and organic phases. The
388
aqueous phase was collected and mixed with 650 L of PM Buffer (Qiagen, 19083 Table S2 .
433
Unless identified otherwise, antibiotic and pharmacologic concentrations were calculated using a 434 maximal clinical dose (taken from the online clinical resource UpToDate.com) or from previous studies 435 (20, (51) (52) (53) (54) , assuming a 20 g mouse that drinks 3 mL water per day. 
527
To test if the two DNA extraction methods affected the resulting microbiota composition data, we 528 processed separate aliquots from the same fecal sample using both methods. We found that the 529 abundances of taxa in the sample processed with both methods were highly correlated (Figures S1A 530 and S1B), suggesting that they represent equivalent ways to assay microbial community composition.
531
In practice, the DIB method was most conducive to the small feces produced by mice and the large 532 majority of mouse samples for this study were processed using this protocol, since the protocol 533 utilizes smaller tubes that can be arrayed into standard 96-well formats. For the remaining mammals, 534 the phenol:chloroform method was used as the number of stools used in the study was less, and the 535 larger stools were more practical to aliquot into the wider 2.0 ml tube used for the phenol:chloroform 536 method.
537
One possible limitation of using DNA content as a measurement of microbiota density is that We quantified the amount of host vs bacterial DNA in several samples by qPCR, and 563 evaluated the qPCR performance against spike-in controls with known combinations of mouse and 564 bacterial DNA. We found that even amongst samples with low microbial density (e.g. samples from 565 mice treated with vancomycin), the DNA content is largely microbial ( Figure S1C ). We were also able 566 to measure the presence of microbial DNA down to concentrations near 1 pg/ L ( Figure S1C ). This 567 allows us to measure microbial density for samples with DNA as low as 100 pg (minimum 568 concentration 1 pg/ L in a 100 L elution volume). Coupled with the ability to subsample the lysate 569 from our DNA extraction protocol, this allows us to measure microbiota density across 5 orders of 570 magnitude for the phenol:chloroform method and 7 orders of magnitude with the DIB protocol.
572
Absolute microbial dynamics and alpha diversity in response to pharmacologics 573 Culture-independent measurements have revealed that antibiotics can disrupt the composition of a 574 healthy gut microbiota (65). We hypothesized that antibiotics may also have an impact on the gut 575 microbiota density. To test this hypothesis, we administered vancomycin in two doses (0.2 mg/mL and 576 0.5 mg/mL) to two sets of SPF C57BL/6J mice and collected fecal pellets before and during treatment.
577
We found that vancomycin exerted selective pressure against susceptible organisms leading to a 578 relative expansion of Verrucomicrobia and Firmicutes in the low and high dose groups respectively 579 ( Figures S3A and S3B ). When we multiplied each taxa's relative abundance by the microbiota density 580 to calculate their absolute abundances, we observed a bloom of Verrucomicrobia in the low dose 581 group ( Figure S3C) . Surprisingly, in the high dose group, we found that vancomycin successfully 582 depleted members of all phyla, including Firmicutes ( Figure S3D ). Microbiota density and alpha 583 diversity were not significantly correlated ( = 0.107; p = 0.557; Spearman; Figure S3E ), as both low 584 dose and high dose vancomycin significantly reduced alpha diversity (p low = 6.10 x 10 -5 and p high = 585 0.00223, final timepoint vs baseline, Mann Whitney; Figure S3F ), while only high dose vancomycin 
593
We homogenized one dog fecal sample and created multiple aliquots for DNA extraction using either 594 the DIB or phenol:chloroform extraction methods.
595
(A) We do not observe evidence of bias introduced by the DNA extraction method chosen, as we 596 observe similar microbial compositions for the multiple aliquots, regardless of extraction method.
597
(B) Relative OTU abundances from DIB and phenol:chloroform extracted samples are highly 598 correlated ( = 0.904, p = 1.82 x 10 -45 , Pearson's correlation). Dots represent average values of an 599 individual OTU abundance across several aliquots processed using each method (n = 8 for DIB, n = 6 600 for phenol:chloroform).
601
(C) We performed qPCR of host and bacterial fractions of mixed mouse/microbial DNA samples.
602
Spike-in samples with known fractions of mouse and bacterial DNA (e.g. B010M090 = 10% bacterial + 603 90% mouse) were quantified with qPCR to validate the potential to identify the origin of DNA in a 604 mixed sample. Samples from mouse fecal pellets across a variety of conditions show that the host 605 contribution to the extracted DNA is small, even for samples with low microbiota density. Red points 606 indicate the true spike-in percentage of bacterial DNA. GF_1, GF_2, GF_3 are host DNA controls of 607 germ-free mouse feces. GF_Spleen is a host DNA control from a germ-free mouse spleen.
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